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creativecommons.org/licenses/by-nc-nd/Abstract Background: A phase I open-label dose-escalation study was conducted to define
the safety, tolerability, and pharmacokinetics (PK) of PankoMab-GEX, a glyco-optimised hu-
manised IgG1, with high affinity to a novel tumour-specific glycopeptide epitope of MUC1
(TA-MUC1) with excellent preclinical anti-tumour activity.
Patients and methods: Seventy-four patients with advanced TA-MUC1-positive carcinomas
received PankoMab-GEX intravenously every 3 (Q3W), 2 (Q2W), or 1 (QW) week in doses
of 1e2200 mg in a three-plus-three dose-escalation design until disease progression
(NCT01222624).
Results: No maximum tolerated dose was reached. Adverse events were mainly mild-to-
moderate infusion-related reactions (IRRs) by the first infusion in 45% of patients. Only
one dose-limiting toxicity, a grade III IRR, was observed. PankoMab-GEX exhibited linear
PK over all doses. Mean terminal half-life was 189  66 h (Q3W), without dose dependency.
A target trough level 50 mg/mL was reached after one infusion with doses 1700 mg Q3W inld University Cancer Center, University Medical Center Hamburg-Eppendorf, Martinistr. 52, D-2000
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W. Fiedler et al. / European Journal of Cancer 63 (2016) 55e635680% of patients. Clinical benefit in 60 evaluable patients included one complete response in a
patient with ovarian cancer treated 483 d and confirmed disease stabilisation in 19 patients
lasting a median (range) of 23 (10e109) weeks. All but two of the patients with clinical benefit
had received a compounded total dose 700 mg over a 3-week period, including 8 of 12 (67%)
patients with ovarian cancer.
Conclusion: PankoMab-GEX is safe, well tolerated, and showed promising anti-tumour activ-
ity in advanced disease. A phase IIb study is ongoing evaluating the efficacy of PankoMab-
GEX as a maintenance therapy in advanced ovarian cancer.
ª 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
MUC1 is a transmembrane mucin expressed on the
ductal cell surface of normal glandular epithelia and on
some haematopoietic cells, which is overexpressed and
aberrantly glycosylated in carcinomas, including cancer
stem cells [1e3]. Tumour-associated alterations of
MUC1 not only favour tumour progression and
metastasis but also turn it into a tumour antigen that
can be targeted specifically for cancer immunotherapy
[4,5]. The molecule’s large extracellular domain consists
mainly of a variable number of normally highly glyco-
sylated peptide tandem repeats, which are under-
glycosylated in tumour-associated MUC1 [6]. Exposure
of immunogenic core protein epitopes and carbohydrate
antigens, such as Tn and Thomsen Friedenreich (TF),
through aberrant glycosylation generate (glyco)peptide
epitopes that provide tumour-specific targets for
immunotherapy [7e11].
PankoMab-GEX is a glyco-optimised humanised
IgG1 monoclonal antibody (MAb) that binds with high
affinity to a novel carbohydrate-induced conformational
epitope (TA-MUC1) on MUC1 that is highly expressed
in a broad variety of carcinomas and is virtually absent
on normal tissues or blood cells [5,8,9,12,13]. Tn or TF
on the highly immunogenic PDTRP sequence of the
tandem repeat are a crucial part of the epitope of
PankoMab-GEX. Its dependence on glycosylation, its
tumour specificity, and its affinity differentiate
PankoMab-GEX from other anti-MUC1 antibodies
[12]. PankoMab-GEX also binds effectively to cancer
stem cells (article in preparation).
Glycosylation of an antibody influences its anti-
tumour efficacy and effector mechanisms [14,15]. The
glycosylation of PankoMab-GEX was optimised with
the GlycoExpress system using human glyco-
engineered production cell lines to give it a human
glycosylation pattern, leading to improved antibody-
dependent cell cytotoxicity (ADCC) and phagocytosis
(ADCP), as well as apoptosis of TA-MUC1-expressing
tumour cells (data on file; Glycotope GmbH, Berlin,
Germany). Tumour cell killing through natural killer
(NK) cell and macrophage-mediated ADCC and ADCPrelies on the constant (Fc) domain of the antibody, but
its efficacy is strongly influenced by Fc gamma receptor
IIIa (FcgRIIIa) polymorphism [16]. Glyco-optimisation
can lead to increased ADCC and ADCP activity [17],
whereby the minimisation of core fucose and the max-
imisation of galactose on the Fc N-glycans play the
crucial roles for enhanced activity, with increase in
bisecting GlcNAc also involved in enhancing ADCC.
PankoMab-GEX has been improved by approximately
fivefold to eightfold in its NK cell-mediated cytotoxicity
and expresses also a particularly strong ADCP against
TA-MUC1-positive tumour cells. Extent of ADCC of
tumour cell lines expressing TA-MUC1 mediated by
PankoMab-GEX depended on TA-MUC1 expression
levels by the individual cell lines and donor peripheral
blood mononuclear cells (PBMC). Maximum specific
lysis of target cells was achieved at PankoMab-GEX
concentrations between 3 and 20 mg/mL depending on
the different donors. The ability of PankoMab-GEX to
induce phagocytosis was shown in a conjugate forma-
tion assay using differently fluorescent-labelled TA-
MUC1-positive target cells and monocyte-derived
macrophages (investigators brochure, data on file; Gly-
cotope GmbH). Co-localisation of macrophages and
tumour cells in the presence of PankoMab-GEX was
observed by flow cytometry and ingestion of tumour
cells by macrophages by confocal microscopy. Pan-
koMab-GEX induced apoptosis of target cell lines
expressing TA-MUC1 after cross-linking by protein G.
It is expected that in vivo, cross-linking of the antibody is
induced by Fcg-receptor-bearing cells. As reported for
MUC1 antibody induced by specific vaccination [18], no
CDC activity of PankoMab-GEX was observed using
human serum complement and the TA-MUC1-positive
cell line ZR-75-1. The in vivo anti-tumour activity of
PankoMab-GEX was studied in nude mice xenografted
with TA-MUC1-positive human tumour cell lines. The
models showed strong anti-tumour activities in dose
levels ranging from 0.02 to 12.5 mg/kg (investigators
brochure, data on file; Glycotope GmbH).
The present study in patients with advanced meta-
static carcinomas was undertaken to investigate the
safety and tolerability of PankoMab-GEX, to establish
W. Fiedler et al. / European Journal of Cancer 63 (2016) 55e63 57the dose for phase II trials, and to evaluate its phar-
macokinetics (PK), immunogenicity, and preliminary
clinical efficacy.
2. Patients and methods
2.1. Study population
This multicentre phase I study was conducted in three in-
stitutions in Italy, Switzerland, and Germany between
November 2009 and May 2013. The study population
consisted of patients with advanced TA-MUC1-positive
solid tumours measurable according to RECIST 1.1
guidelines [19] that had failed and exhausted available
standard therapy and had progressive disease at study
entry. TA-MUC1 positivity was assessed by PankoMab-
GEX staining of tumour sections (Supplement A). Inclu-
sion/exclusion criteria are summarised in Supplement A.
Local ethics committee approval and patient’s writ-
ten informed consent were obtained. The study was
conducted in accordance with Good Clinical Practice
guidelines and the Declaration of Helsinki.
2.2. Study design and dosing
PankoMab-GEX (PankoMab-GEX; Glycotope
GmbH) was administered intravenously in 250e500 mL
saline, in 2 h for doses up to 500 mg and 3 h for higher
doses, in three dosing schedules: every 3 (Q3W), 1 (QW),
and 2 weeks (Q2W). Patients were sequentially enrolled
in a three-plus-three dose-escalation design, starting
with Q3W (1, 10, 50, 150, 300, 500, 700, 900, 1100, 1300,
1500, 1700, and 2200 mg flat dose), followed by QW
(300, 400, 500, 600, and 700 mg) once the Q3W cohort
of 900 mg was completed. Based on PK evaluation,
Q2W (a 900-mg loading dose followed 1 week later by
1200 mg every 2 weeks) was tested. Premedication was
introduced in the course of the study (H1 and H2 an-
tagonists, paracetamol and corticosteroids) to minimise
infusion-related reactions (IRR). Treatment was
continued until disease progression, occurrence of
intolerable toxicity, or withdrawal of consent.
2.3. Dose-limiting toxicity
Toxicities were graded according to NCI CTCAE,
version 3.0. Dose-limiting toxicity (DLT) was defined as
any haematological or non-haematological toxicity of
grade III or more, a grade II allergic reaction at first
infusion, or a grade II autoimmune reaction during or
after first infusion of PankoMab-GEX. Three evaluable
patients were entered at each dose level. If a DLT
occurred, the cohort was expanded to six patients before
escalating to the next dose level; an maximum tolerated
dose (MTD) was reached if more than two patients
experienced a DLT at any given dose in the first cycle.2.4. Pharmacokinetic analysis
Blood for PK analysis was collected at specified time
points, and PankoMab-GEX serum levels were
measured (Glycotope GmbH; see Supplement A).
PK parameters were derived from the individual pa-
tient serum concentrationetime profiles using non-
compartmental methods (FUNCALC 3; Prolytic
GmbH, Frankfurt, Germany). The maximum (Cmax)
and minimum (Cmin) serum concentration after admin-
istration were directly taken from analytical data. Dose
linearity and proportionality of the PK parameters
Cmax, Cmin, AUC0eN and AUC0etlast were investigated
over the dose range, based on the individual values by
linear regression analysis. A trough level of 50 mg/mL of
the drug was set as target for the study based on in vitro
tests in which maximum ADCC is achieved at
PankoMab-GEX concentrations of 3e20 mg/mL
depending on the FcgRIIIa polymorphism of the donor
PBMCs and reported trough levels of established anti-
bodies, such as cetuximab and trastuzumab, which also
mediate ADCC [20,21]. Accumulation of PankoMab-
GEX was assessed by dividing the trough concentra-
tions after the second and subsequent doses by the
trough concentration after the first dose.
2.5. Immunogenicity
Samples were screened for anti-drug antibody (ADA)
and ADA titration was performed on samples confirmed
as positive (Glycotope GmbH; see Supplement A). Cy-
tokines IL-1b, IL-8, IFN-g and TNF-a serum levels
were analysed during the first infusion at specified time
points. Additionally, factor C3a (19 patients) and
eosinophilic cationic protein (ECP, 27 patients) were
measured within 24 h after the first PankoMab-GEX
infusion.
2.6. MUC1 serum levels
MUC1 serum levels were measured for Q3W and QW
with a CA15-3 commercial ELISA (MP Biomedicals,
Orangeburg, NY, USA).
2.7. Tumour assessment
Tumour response in patients with measurable disease
was evaluated according to RECIST 1.1 guidelines [16].
Baseline imaging was assessed within 4 weeks before the
first PankoMab-GEX dose and then every 8 weeks until
withdrawal from study. Imaging included computed
tomography and/or magnetic resonance imaging of
target lesions. Clinical activity was assessed by
measuring the response (complete response [CR], partial
response [PR], stable disease [SD]). SD and PR needed
imaging confirmation after 8 and 4 weeks, respectively.
W. Fiedler et al. / European Journal of Cancer 63 (2016) 55e63582.8. Statistical analysis
Descriptive statistics were used on the intent-to-
treat population to summarise patient demographics
and baseline characteristics, treatment administration,
safety parameters, PK variables, and efficacy end-points
(SAS 9.1). The distribution of anti-tumour responses
was analysed in contingency tables according to dose
levels.
3. Results
3.1. Patient characteristics
Demographics and disease characteristics of the 74 pa-
tients enrolled in the study are contained in Table 1.
Upon entering the study, all patients had progressive
advanced metastatic disease and had exhausted avail-
able standard treatment procedures.Table 1
Demographic and baseline disease characteristics of the study population.
Q3W (N Z 52)
Age in years (median, range) 58 (25e81)
Gender (N, %)
- Male 15 (28.8)
- Female 37 (71.2)
Ethnic origin (N, %)
- Caucasian/white 51 (98.1)
- Hispanic 1 (1.9)
ECOG performance status (N, %)
- 0 30 (57.7)
- 1 22 (42.3)
Time from diagnosis in months (median, range)a 37.6 (6e290)
Primary tumour (N, %)
- Colorectal cancer 21 (40.4)
- Ovarian cancer 16 (30.8)
- Breast cancer 6 (11.5)
- Non-small cell lung cancer e
- Pancreatic cancer 3 (5.8)
- Gastro-oesophageal cancer 1 (1.9)
- Bladder cancer 1 (1.9)
- Prostate cancer 1 (1.9)
- Pseudomyxoma peritonei 1 (1.9)
- Cholangiocarcinoma e
- Adenoid cystic carcinoma (salivary gland) 1 (1.9)
- Cervix carcinoma e
- Oropharyngeal carcinoma 1 (1.9)
- Carcinoma of unknown primary e
Prior antibody therapy (N, %)
Any prior antibody therapyb 22 (42.3)
- Bevacizumab 15 (28.8)
- Cetuximab 9 (17.3)
- Panitumumab 1 (1.9)
- Ramucirumab 1 (1.9)
- Trastuzumab 2 (3.8)
CA15-3 serum levels in U/mL, (median, range)c 30 (7e1633)
ECOG Z Eastern Cooperative Oncology Group.
a Date of first dose of study drug e date of initial diagnosis of the disea
b Nine patients received two antibodies.
c CA15-3 was measured before start of the first (all patients) and the sec3.2. Drug exposure, safety and tolerability
The three dosing schedules had similar adverse event
profiles. Reason for study termination was disease pro-
gression (65 cases), death (1), adverse event (4), with-
drawal of informed consent (1), lost to follow-up (1),
and investigator’s decision (2).
Number of infusions administered, drug exposure
and incidence of IRRs are listed in Table 2. The ma-
jority of IRRs was mild-to-moderate and resolved
quickly after a pause in the infusion and symptomatic
medication. Infusion duration was extended from 2 to
3 h after an IRR grade II (Q3W, 500 mg), initially
erroneously classified, as an allergic reaction occurred.
The drug was withdrawn and three additional patients
were recruited at the same dose level without further
incidents. A grade III IRR, classified as a DLT, was
observed in a patient (Q3W, 900 mg; premedication,
anti-histamine), consisting of facial rash, abdominalQW (N Z 18) Q2W (N Z 4) Total (N Z 74)
54.5 (41e74) 58 (50e70) 57 (25e81)
5 (27.8) 1 (25) 21 ( 28.4)
13 (72.2) 3 (75) 53 ( 71.6)
18 (100) 4 (100) 73 (98.6)
1 (1.4)
7 (38.9) 3 (75) 40 (54.1)
11 (61.1) 1 (25) 34 (45.9)
27.3 (12e103) 41 (7e104) 35 (6e290)
3 (16.7) 1 (25) 25 (33.8)
3 (16.7) 1 (25) 20 (27)
1 (5.6) e 7 (9.5)
7 (38.9) e 7 (9.5)
2 (11.1) e 5 (6.8)
1 (5.6) e 2 (2.7)
e e 1 (1.4)
e e 1 (1.4)
e e 1 (1.4)
1 (5.6) e 1 (1.4)
e e 1 (1.4)
e 1 (25) 1 (1.4)
e e 1 (1.4)
e 1 (25) 1 (1.4)
5 (27.8) 1 (25) 28 (37.8)
4 (22.2) 1 (25) 20 (27)
2 (11.1) 1 (25) 12 (16.2)
0 0 1 (1.4)
0 0 1 (1.4)
1 (5.6) 0 3 (4.1)
33 (14e857) 25 (19e49) 31 (7e1633)
se þ 1.
ond infusion (27 and 17 patients for Q3W and QW, respectively).
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W. Fiedler et al. / European Journal of Cancer 63 (2016) 55e63 59pain, choking sensation, and hypotension that resolved
quickly after withdrawal of the drug and symptomatic
medication. Three additional patients were recruited at
the same dose level; no further DLTs were observed in
the course of the study. An MTD was not reached. The
drug was withdrawn in one additional patient who
experienced a grade II IRR during the second infusion
(total of drug withdrawals due to IRRs 3 of 74, 4%).
Only 4 of 63 (6.3%) patients experienced mild-to-
moderate IRRs with the second infusion; the patients
had received premedication. Only six IRRs (1.9%) were
observed in all 322 subsequent infusions, of which three
were of grade II, and the patients had received no
premedication.
Initially, no premedication was administered. It was
introduced for the first and all subsequent infusions
from Q3W, 900 to 1700 mg dose, but was later restricted
to the first infusion or the one following an IRR in the
previous infusion for Q3W 2200 mg, Q2W and QW to
limit the negative effect of steroids on ADCC [22].
Treatment emergent adverse events (TEAEs) other
than IRR possibly related to the drug were mild-to-
moderate and few in number. Seven patients experi-
enced a possibly drug-related grade III TEAE: three
cases of asthenia and one case each of decreased white
blood cell count, increased transaminases, nausea, and
pneumonia were observed. No grade IV or V drug-
related TEAE occurred.
No increase of cytokines, C3a, or ECP serum levels
was observed. Seven patients developed low titres of
ADA between the second and tenth infusion and 28
d after the last infusion. The highest log 2 titre was 6.91.
3.3. Pharmacokinetics
Mean serum concentrations of PankoMab-GEX per
dose cohort measured in the Q3W schedule during the
first infusion are illustrated in Fig. S1 and PK parame-
ters for the three schedules are contained in Table S1.
PK could be evaluated in 49 of 52 patients in the Q3W
schedule. PankoMab-GEX exhibited linear PK with
respect to dose across the whole 1- to 2200-mg dose
range, as demonstrated by the dose-linear increase in
Cmax, Cmin and AUC0etlast (Fig. S2). No dose de-
pendency was observed for t1/2. For Q3W, t
1/2
(mean  standard deviation) was 189  66 h; compa-
rable values were obtained for Q2W. Lower t1/2 values
(108  28 h) were observed for QW, reflecting the
shorter dosing interval. CL and VZ showed comparable
values over the dose range.
A trough level (Cmin) of 50 mg/mL was reached after
one infusion with doses 1700 mg Q3W and 500 mg
QW and in Q2W in 8 of 10 (80%), 11 of 11 (100%) and
1 of 3 (33%) evaluable patients, respectively. The
accumulation ratios of Cmin in Q3W after three in-
fusions (seven patients) ranged from 1.22 to 2.36; a
steady state was achieved after three infusions in three
Fig. 1. Concentrationetime profiles of repeated infusions of
PankoMab-GEX measured in individual patients before and 3 h
after start of infusion: (A) three-weekly schedule (Q3W), dose
W. Fiedler et al. / European Journal of Cancer 63 (2016) 55e6360of seven patients, with very small variations observed
in the other four patients. The accumulation ratios of
Cmin in QW after five infusions ranged from 1.91 to
3.49 without dose dependency; a steady state had not
been attained in most of the patients. No reliable
statement can be given for Q2W due to the low
number of patients. An example of individual serum
concentrationetime profiles for each dose schedule is
illustrated in Fig. 1.
3.4. MUC1 serum levels
MUC1 (CA15-3) serum levels before first infusion of
PankoMab-GEX are contained in Table 1. The per-
centage of CA15-3 (mean  standard deviation) in
relation to its corresponding baseline values was
89.8  36.8% and 80.8  21.9% before the second
infusion, for Q3W and QW, respectively.
3.5. Clinical anti-tumour activity
All patients had progressive disease at study entry.
Tumour response was evaluated in 60 patients. Fourteen
patients were not evaluated because of either premature
withdrawal (13 patients) or lost to follow-up (1 patient). A
clinical benefit was observed in 28 of 60 (47%) patients: 1
CR and 27 SD,with 19 of the SD confirmed. Anti-tumour
activity (1CRand 17 confirmed SD)was observed in 18 of
42 (43%) of patients treatedwith a compounded total dose
of PankoMab-GEX 700 mg over a 3-week period, but
only in 2 of 18 (11%) patients who received <700 mg
PankoMab-GEX in the same period (p Z 0.019). No
correlation was found between MUC1 expression levels
on the primary tumour and clinical response.
One patient with serous ovarian cancer (Q3W,
1100 mg, 23 infusions) progressive after debulking
surgery and chemotherapy with carboplatin/paclitaxel
and carboplatin/doxorubicin achieved CR before pro-
gressing after 483 d on therapy (Fig. 2). Twenty-three
of 42 (53%) patients treated with a compounded total
dose 700 mg PankoMab-GEX over a 3-week period
had a best overall response of SD (median 19 weeks,
range 9e109 weeks) that was confirmed in 17 (40%)
patients (median 23 weeks, range 10e109 weeks), 10
patients in Q3W, 3 in Q2W and 4 in QW. A patient
with non-small cell lung cancer (NSCLC) (QW,
600 mg, 36 infusions) progressive after three chemo-
therapy regimens and radiotherapy achieved a (un-
confirmed) PR after 164 d of treatment; the response
was classified as an SD, which lasted 295 d. The
longest confirmed SD (759 d) with long-lastingcohort 2200 mg, N 6; (B) weekly dosing schedule (QW), dose
cohort 500 mg, N 3; (C) two-weekly dosing schedule (Q2W),
1200 mg (time point 0), preceded a week before by a 900-mg
loading dose, N 3. The dotted line indicates the targeted trough
level of 50 mg/mL of PankoMab-GEX.
Fig. 2. Sum of longest diameter (SLD, in mm) of target lesions (two peritoneal nodules) and CA 125 serum levels (U/mL) during treatment
with 1100 mg PankoMab-GEX every 3 weeks (Q3W) in a patient with a serous papillary carcinoma of the ovary. An initial increase of
target lesions and CA 125 levels was followed by a slow and sustained decrease until normalisation of CA 125 levels by day 272 and
disappearance of target lesions by day 315 of treatment. Non-target lesions (axillary, para-aortal and aorto-caval lymph nodes, all smaller
than 15 mm at baseline) had all disappeared by day 191 of treatment. The patient received a total of 23 infusions until progression after
483 d of treatment.
W. Fiedler et al. / European Journal of Cancer 63 (2016) 55e63 61stabilisation of all target lesions (21% reduction) and
reduction of CA 125 to normal levels was observed in
a patient (Q3W, 900 mg, 33 infusions) diagnosed with
pseudomyxoma peritonei stage IV 2 years previously
and progressive after neoadjuvant chemotherapy,
debulking surgery and chemotherapy. Clinical benefit
was observed in a broad variety of primary tumours,
but more frequently in ovarian and NSCLC. Primary
tumours of patients with clinical benefit included 8 of
15 (53%) ovarian cancer and 3 of 7 (43%) NSCLC.
Seven patients experienced a confirmed SD for at least
210 d, three of them (43%) had ovarian cancer.
Waterfall plots of changes from baseline of target le-
sions are shown in Fig. 3.
4. Discussion
This is the first clinical study of a humanised mono-
clonal antibody directed to a MUC1 conformational
glycopeptide epitope highly expressed in adenocarci-
nomas and glycoengineered for enhanced Fc-mediated
anti-tumour activity. PankoMab-GEX was safe and
very well tolerated after repeated administration in
three different schedules. The MTD was not reached
after a maximum dose of 2200 mg. Similar to other
therapeutic MAbs, IRRs were mostly mild-to-moder-
ate and confined to the first infusion [23]. IRRs were
not associated with cytokine release, activation of
complement, or an allergic reaction. Only seven pa-
tients developed a low ADA response that was not
related to dose and did not interfere with prolonged
treatment. Interestingly, five in seven of them had SD,
ranging from 133 to 760 d.Consistent with its high specificity, PankoMab-GEX
exhibits a long half-life that allows one to three weekly
schedules and shows linear PK over all doses. The lack
of an antigen sink agrees with the virtual absence of
expression of its epitope on normal tissues. Circulating
MUC1 did not affect the linearity of distribution of the
drug, reflecting a lack of significant binding of
PankoMab-GEX to it. The target trough level of 50 mg/
mL was amply reached at the higher doses with all three
administration schedules. Based on the PK and clinical
results, a loading dose of 500 mg PankoMab-GEX fol-
lowed a week later by 1700 mg administered every 3
weeks was chosen for the first phase II study as a
maintenance therapy in ovarian carcinoma.
As PankoMab-GEX binds to a tumour-specific
conformational glycopeptide epitope on MUC1 that is
extensively expressed in many tumour types, and its
potential for immunotherapy is very wide. TA-MUC1 is
expressed in >80% of lung, breast and ovarian adeno-
carcinomas [24e26] and in 92e100% of clear cell,
endometroid and serous adenocarcinomas of the ovary
[26]. A clinical benefit that was more frequent at higher
doses was observed in 47% of evaluable patients, all with
advanced progressive disease at study entry and a broad
variety of adenocarcinomas. The best responses and the
highest frequency of confirmed SD were observed in
patients with ovarian and lung cancer. In the subgroup
of ovarian cancer patients, the clinical benefit rate at
total dose levels of 700 mg was 75% (9 of 12),
including one complete responder and SD in four pa-
tients resistant/refractory to platinum therapy. As is
characteristic of immunotherapy [27], responses take
time to establish and can be preceded by an initial
Fig. 3. Waterfall plots of the best percent change from baseline in sum of longest diameters (SLD) for target lesions. Baseline is defined as the last non-missing value before the first dose of
PankoMab-GEX. Only 58 patients in the total population (N 74) had valid baseline and post-baseline values. Tumour assessment was not performed in 16 patients because of early
withdrawal due to clinical deterioration (N 10) or adverse event (N 3) or no target lesions (N 3). The dotted lines indicate the cutoff for PR (e30%) and progressive disease (þ20%). Bars
marked with an asterisk denote 13 patients with stable target lesions but progression because of new lesions. Abbreviations: Ad.cystCa, adenoid cystic carcinoma; BC, breast cancer; CRC,
colorectal cancer; CUP, carcinoma of unknown origin; GCA, gastric cancer; HNC, head and neck cancer; NSCLC, non-small cell lung cancer; OVCA, ovarian cancer; PanC, pancreatic
cancer; PMP, pseudomyxoma peritonei; PrCa, prostate cancer.
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the patient who developed a CR (Fig. 2).
In conclusion, PankoMab-GEX was very well toler-
ated with mild-to-moderate adverse events, mainly IRRs
at first infusion. Following the promising preliminary
efficacy in patients with ovarian cancer, a double-blind,
placebo-controlled, randomised phase IIb study in pa-
tients with advanced ovarian carcinoma has been started.
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